Stock Analysis of Werewolf Therapeutics Inc (HOWL) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code HOWL
Close 4.72
Change -0.160 / 3.28 %
Volume 114618
Vol Change -20590.00 / 15.23 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Low Growth Stock
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Werewolf Therapeutics Inc
PE (TTM)

-4.31

Very Poor
Price / Book

1.54

Good
Price / Sales

11.05

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

205109 K

Enterprise Value

84007.49 K

ROA (TTM)

-22.87

Very Poor
ROE (TTM)

-35.78

Very Poor
Net Margin (TTM)

-256.33

Very Poor
Revenue

56.85 %

25725.00 K
Net Profit

30.69 %

-37295.00 K
Debt to Equity

0.308

Very Good
Altman Z Score

-0.557

Very Poor
Quick Ratio

0

Poor
Cash Ratio

8.02

Excellent


Highs/Lows of Werewolf Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week5.05 6.53 % 1.54 % 5.414.415-May-2413-May-24
Two Week6.07 22.24 % 3.42 % 6.24044.406-May-2413-May-24
One Month5.84 19.18 % 5.60 % 6.894.429-Apr-2413-May-24
Three Month6.89 31.49 % 5.95 % 8.19394.426-Feb-2413-May-24
Six Months2.3 105.22 % 17.48 % 8.19392.2926-Feb-2420-Nov-23
One year2.74 72.26 % 27.52 % 8.19391.573526-Feb-2424-Oct-23
Two year4.86 2.88 % 29.70 % 8.19391.3926-Feb-2407-Dec-22


Technical View of Werewolf Therapeutics Inc
RSI

35.91

Neutral
MACD

-0.325

Bearish
ADX

19.27

Bearish
Super Trend

6.30

Strong Bearish
Williams %R

-86.32

Mild Bullish
CCI

-115.30

Mild Bullish


EMA 5

4.88

Strong Bearish
EMA 15

5.31

Mild Bearish
EMA 50

5.67

Strong Bearish
EMA 100

5.35

Strong Bearish
SMA 100

5.70

Strong Bearish
SMA 200

4.10

Bullish
SMA 5 / 20

4.77 / 5.73

Strong Bearish
SMA 15 / 50

5.51 / 5.85

Mild Bearish
SMA 50 / 200

5.85 / 4.10

Bullish




Charts of Werewolf Therapeutics Inc


Returns of Werewolf Therapeutics Inc with Peers
Period / StockHOWLINGNOGIPROF
1 Week-6.53%4.37%14.77%7.24%
1 Mth-19.18%27.05%10.38%6.35%
3 Mth-31.49%-11.96%-7.34%-2.47%
6mth105.22%53.83%60.32%-22.23%
1 Year72.26%-20.88%6.54%-38.86%
2 Year-2.88%-65.89%-62.03%13.10%
5 Years--87.63%-93.67%22.20%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Werewolf Therapeutics Inc with Peers
Ratio / StockHOWLINGNOGIPROF
PE-4.31-2.13-0.477-6.52
P/B1.540.8680.4284.38
ROA-22.87-27.69-79.06-51.94
ROE-35.78-40.85-89.70-67.15
Debt To Equity0.3080.01780.00400.236
Revenue25725.00 K
56.85 % 		327855 K
13.09 % 		149205 K
2.33 % 		6447.00 K
3.50 %
Net Income-37295.00 K
30.69 % 		-132504.00 K
58.17 % 		-229477.86 K
1506.65 % 		-29187.00 K
1.81 %


Technicals of Werewolf Therapeutics Inc with Peers
Technical / StockHOWLINGNOGIPROF-
ADX19.2731.5715.3027.44
CMF-0.04650.00940.0141-0.178
MFI14.8391.4271.3744.56
RSI35.9166.4055.5455.47
MACD Abv SignalFalseTrueTrueTrue
Price Above 50 MAFalseTrueFalseTrue-
Price Above 200 MATrueTrueTrueFalse-


About : Werewolf Therapeutics Inc

Address : 200 Talcott Ave, Watertown, MA, United States, 02472
Tel : (617) 952-0555
URL : https://werewolftx.com
Code : HOWL, ISIN : US95075A1079, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 30_Apr_2021
Employee Count : 47

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)